NCT00844064 2019-02-15
Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
Isarna Therapeutics GmbH
Phase 1 Completed
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH